This report studies the global market size of Tuberculosis Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Tuberculosis Drug in these regions. This research report categorizes the global Tuberculosis Drug market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis. Tuberculosis (TB) is an infectious disease, which is caused by Mycobacterium tuberculosis. These bacteria generally infect human lungs. However, it can infect other body parts/organs as well. Three major types of tuberculosis are found: latent, active, and drug-resistant tuberculosis. Symptoms are not identifiable in case of latent tuberculosis, due to presence of an inactive form of bacteria. In active tuberculosis, symptoms are clearly visible and they can spread from one person to another. Coughing for more than two weeks, chest pain, coughing up blood, chills, fatigue, unintentional weight loss, fever, and loss of appetite are some of the common symptoms of active tuberculosis. HIV/AIDS, severe kidney disease, cancer, diabetes, and malnutrition are some of the key risk factors generally found to be associated with tuberculosis. Growing prevalence of multi-drug resistant tuberculosis is driving the tuberculosis drugs market. Drug shortages is a major restraint for the tuberculosis drugs market, especially in low- to medium-income countries of the world. Tuberculosis associated with diseases such as HIV/AIDS and conditions such as obesity is extremely difficult to manage. The tuberculosis drugs market can be segmented based on drug class, disease type, end-user, and region. In terms of drug class, the market can be categorized into first-line therapy, second-line therapy, and combination therapy. Isoniazid, Pyrazinamide, Rifampin, and Ethambutol majorly constitute the first-line therapy for TB; while Streptomycin, Capreomycin, Ethionamide, Levofloxacin, and Gatifloxacin are generally considered as a part of the second-line therapy. Second-line therapy is expected to be a rapidly growing segment of the tuberculosis drugs market. In 2017, the global Tuberculosis Drug market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Tuberculosis Drug market based on company, product type, application and key regions. The various contributors involved in the value chain of Tuberculosis Drug include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Tuberculosis Drug include Lupin Otsuka Novel Products Pfizer Sanofi Market Size Split by Type First-line Anti-TB Drugs Second-line Anti-TB Drugs Market Size Split by Application Active TB Latent TB Market size split by Region North America United States Canada Mexico Asia-Pacific China India Japan South Korea Australia Indonesia Singapore Malaysia Philippines Thailand Vietnam Europe Germany France UK Italy Spain Russia Central & South America Brazil Rest of Central & South America Middle East & Africa GCC Countries Turkey Egypt South Africa The study objectives of this report are: To study and analyze the global Tuberculosis Drug market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025. To understand the structure of Tuberculosis Drug market by identifying its various subsegments. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). Focuses on the key global Tuberculosis Drug manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Tuberculosis Drug with respect to individual growth trends, future prospects, and their contribution to the total market. To project the value and volume of Tuberculosis Drug submarkets, with respect to key regions (along with their respective key countries). To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. To strategically profile the key players and comprehensively analyze their growth strategies. In this study, the years considered to estimate the market size of Tuberculosis Drug are as follows: History Year: 2013-2017 Base Year: 2017 Estimated Year: 2018 Forecast Year 2018 to 2025 This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Tuberculosis Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources. For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents 1 Study Coverage 1.1 Tuberculosis Drug Product 1.2 Key Market Segments 1.3 Key Manufacturers Covered 1.4 Market by Type 1.4.1 Global Tuberculosis Drug Market Size Growth Rate by Type 1.4.2 First-line Anti-TB Drugs 1.4.3 Second-line Anti-TB Drugs 1.5 Market by Application 1.5.1 Global Tuberculosis Drug Market Size Gr
